Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335497 · ClinicalTrials.gov registry record · Phase 1
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced / Metastatic Solid Tumors, sponsored by Crescent Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 5
- Study locations
NCT07335497 is a Phase 1 study of Locally Advanced / Metastatic Solid Tumors that is actively recruiting participants, run by Crescent Biopharma. The registered enrollment target is 290 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT07335497, a Phase 1 study of Locally Advanced / Metastatic Solid Tumors, is actively recruiting participants, sponsored by Crescent Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG CR-001
Study Locations (5)
Florida
- Clinical Study Site - Orlando
- Clinical Study Site - Sarasota
Colorado
- Clinical Study Site - Denver
Tennessee
- Clinical Study Site - Nashville
Texas
- Clinical Study Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07335497
The ClinicalTrials.gov registry entry for NCT07335497 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crescent Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced / Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CR-001 is the first listed.
NCT07335497 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07335497 about?
NCT07335497 is a clinical study titled "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT07335497?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2026-02-17. Estimated completion is 2029-02.
What conditions does trial NCT07335497 study?
This clinical trial studies the following conditions: Locally Advanced / Metastatic Solid Tumors.
What interventions are being tested in trial NCT07335497?
The interventions under investigation include: CR-001 (DRUG).
Who is sponsoring clinical trial NCT07335497?
This trial is sponsored by Crescent Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07335497 being conducted?
This trial has 5 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.